This page uses content from Wikipedia and is licensed under CC BY-SA.
SoRI-9409 is a mixed mu opioid receptor partial agonist and delta opioid receptor antagonist, used in biomedical research. It produces moderate analgesic effects without development of tolerance and with reduced withdrawal symptoms compared to standard opioid analgesics, as well as showing anti-addictive effects that may be useful in the treatment of  alcoholism. 
Wells JL, Bartlett JL, Ananthan S, Bilsky EJ (May 2001). "In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence". The Journal of Pharmacology and Experimental Therapeutics. 297 (2): 597–605. PMID 11303048.
Nielsen CK, Simms JA, Pierson HB, Li R, Saini SK, Ananthan S, Bartlett SE (December 2008). "A novel delta opioid receptor antagonist, SoRI-9409, produces a selective and long-lasting decrease in ethanol consumption in heavy-drinking rats". Biological Psychiatry. 64 (11): 974–81. doi: 10.1016/j.biopsych.2008.07.018. PMC . 3888668 PMID 18774553.
Nielsen CK, Simms JA, Bito-Onon JJ, Li R, Ananthan S, Bartlett SE (March 2012). "The delta opioid receptor antagonist, SoRI-9409, decreases yohimbine stress-induced reinstatement of ethanol-seeking". Addiction Biology. 17 (2): 224–34. doi: 10.1111/j.1369-1600.2010.00295.x. PMC . 3906128 PMID 21309957.